Introduction: Calcium use during cardiac arrest has conflicting results in terms of efficacy. Therefore, we performed a systematic review evaluating the role of calcium administration in cardiac arrest.
Methods: We searched PubMed, Cochrane, and EMBASE for studies comparing calcium administration versus no calcium administration during cardiac arrest. The study was prospectively registered in PROSPERO (CRD42022316641) adhering to PRISMA guideline recommendations. The primary outcome was return of spontaneous circulation (ROSC) or survival at one hour. The secondary outcomes included survival to discharge or at 30 days, and favorable neurologic outcomes at 30 and 90 days. We planned to perform a random-effects meta-analysis of low risk of bias studies. We evaluated risk of bias with RoB-2 and ROBINS-I.
Results: We identified 1,921 articles and included ten studies with 2509 patients. We were not able to perform a meta-analysis with low-risk of bias studies as only one study was found to be at low-risk of bias. However, for the primary outcome, the three RCTs included showed no benefit with calcium administration during cardiac arrest for ROSC. For the secondary outcomes, based on the most recent study and lower risk of bias, there was a neutral effect for survival to discharge or at 30 days and neurologic outcomes at 30 days. However, there was unfavorable neurologic outcomes at 90 days.
Conclusion: Based on our results, calcium administration in cardiac arrests shows no benefit and can cause harm. Further studies on this matter are likely not advisable.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9550532 | PMC |
| http://dx.doi.org/10.1016/j.resplu.2022.100315 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comprehensive evaluation of low-carbon cementitious materials prepared with industrial by-product calcium carbide residue (CCR) as alkali source.
Environ Res
January 2025
Science and Technology Innovation Center of Smart Water and Resource Environment, Northeastern University, Shenyang 110819, China; School of Resources and Civil Engineering, Northeastern University, Shenyang 110819, China; Liaoning Institute of Technological Innovation in Solid Waste Utilization, Northeastern University, Shenyang 110819, China.
The preparation of low-carbon cementitious materials through the synergistic coupling of multiple solid wastes has great potential for development, which can improve the problems of resource shortage and environmental pollution. In this paper, a new type of supersulfated cement was developed by using calcium carbide residue (CCR) as an alkaline activator. The effects of CCR content on the mechanical properties and hydration behaviors of the samples under steam curing conditions were discussed.
View Article and Find Full Text PDFUpdate in Cardiovascular Prevention: From Risk Scores to Imaging.
R I Med J (2013)
February 2025
Division of Cardiology, Department of Medicine, Brown University, Providence RI.
Atherosclerotic cardiovascular disease (ASCVD) remains the leading cause of morbidity and mortality worldwide. This review explores the evolving evidence base surrounding ASCVD prevention, particularly regarding nontraditional biomarkers, risk scores, and cardiovascular imaging modalities. Additionally, this review examines cardiovascular risk scores, including the PREVENT and MESA-CHD scores, which incorporate both traditional and nontraditional factors, thereby aspiring to offer a more equitable and precise risk assessment.
View Article and Find Full Text PDFEnhanced Antitumor Efficacy and Reduced Toxicity in Colorectal Cancer Using a Novel Multifunctional Rg3- Targeting Nanosystem Encapsulated with Oxaliplatin and Calcium Peroxide.
Int J Nanomedicine
January 2025
Department of Biopharmacy, School of Pharmaceutical Sciences, Jilin University, Changchun, People's Republic of China.
Article Synopsis
- Colorectal cancer (CRC) is a major cause of cancer deaths, and oxaliplatin (OXA) is a primary treatment that faces challenges due to the tumor microenvironment (TME).
- A new multifunctional nanosystem, Rg3-Lip-OXA/CaO, uses Ginsenoside Rg3 liposomes to target CRC cells, delivering OXA and calcium peroxide (CaO) together.
- Research showed that this nanosystem had good stability and release properties, effectively targeted cancer cells, and significantly suppressed tumor growth in mice, while also showing manageable acute toxicity.
Description of STRIVE-ON Study Protocol: Safety and Tolerability of GTX-104 (Nimodipine Injection for IV Infusion) Compared with Oral Nimodipine in Patients Hospitalized for Aneurysmal Subarachnoid Hemorrhage (aSAH): A Prospective, Randomized, Phase III Trial (STRIVE-ON).
Neurocrit Care
January 2025
Department of Neurology, Mayo Clinic, Rochester, MN, USA.
Oral nimodipine is the only drug approved in North America for patients with aneurysmal subarachnoid hemorrhage (aSAH). However, bioavailability is variable and frequently poor, leading to fluctuations in peak plasma concentrations that cause dose-limiting hypotension. Furthermore, administration is problematic in patients who cannot swallow.
View Article and Find Full Text PDFShort-term evaluation of renal biochemical parameters in dogs completing chemotherapy for lymphoma.
Aust Vet J
January 2025
North Shore Veterinary Specialist & Emergency Centre, Artarmon, New South Wales, Australia.
Objectives: To identify if chemotherapeutic drugs in the CHOP-based protocol led to an increase in renal parameters in dogs with lymphoma during therapy and investigate whether factors such as prednisolone use or age affected this result.
Methods: Data were obtained retrospectively from private referral practice records of dogs diagnosed with lymphoma receiving a CHOP-based chemotherapy protocol between 2015 and 2019. Dogs included received a CHOP-based protocol as their first treatment, received four full cycles and were in remission at the end of the protocol.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!